# DETER-SMM (NCT03937635)

> Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03937635
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Smoldering Plasma Cell Myeloma
- Interventions: Daratumumab; Dexamethasone; Lenalidomide; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 288
- Primary outcome: Overall survival (OS)
- Primary outcome: Functional Assessment of Cancer Therapy-General (FACT-G) score

## Indexed commentary on DETER-SMM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 624
- Bluesky threads: 12
- YouTube: 8
- Podcasts: 3
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=deter-smm-nct03937635

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03937635", "email": "<work email>"}; the inbox owner confirms by the emailed link.